USD
$0.00
(0.00%
)At Close (As of Oct 21, 2025)
$998.73M
Market Cap
32.14
P/E Ratio
0.21
EPS
$10.14
52 Week High
$5.58
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $289M |
Total Revenue | $349M |
Cost Of Revenue | $60M |
Costof Goods And Services Sold | $60M |
Operating Income | $59M |
Selling General And Administrative | $225M |
Research And Development | $12M |
Operating Expenses | $230M |
Investment Income Net | - |
Net Interest Income | -$1M |
Interest Income | - |
Interest Expense | $1M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $6M |
Income Before Tax | $57M |
Income Tax Expense | $15M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $42M |
Comprehensive Income Net Of Tax | - |
Ebit | $58M |
Ebitda | $64M |
Net Income | $42M |
Field | Value (USD) |
---|---|
Total Assets | $264M |
Total Current Assets | $192M |
Cash And Cash Equivalents At Carrying Value | $104M |
Cash And Short Term Investments | $104M |
Inventory | $24M |
Current Net Receivables | $56M |
Total Non Current Assets | $72M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $12M |
Intangible Assets Excluding Goodwill | $12M |
Goodwill | $19M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $7.8M |
Other Non Current Assets | - |
Total Liabilities | $71M |
Total Current Liabilities | $46M |
Current Accounts Payable | $7.4M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1M |
Total Non Current Liabilities | $25M |
Capital Lease Obligations | - |
Long Term Debt | $18M |
Current Long Term Debt | $1M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $25M |
Other Current Liabilities | $37M |
Other Non Current Liabilities | $7.4M |
Total Shareholder Equity | $193M |
Treasury Stock | - |
Retained Earnings | -$91M |
Common Stock | $147K |
Common Stock Shares Outstanding | $149M |
Field | Value (USD) |
---|---|
Operating Cashflow | $66M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $6M |
Capital Expenditures | $1.7M |
Change In Receivables | - |
Change In Inventory | -$2.4M |
Profit Loss | - |
Cashflow From Investment | -$9.6M |
Cashflow From Financing | -$34M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$2.6M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $42M |
Field | Value (USD) |
---|---|
Gross Profit | $289M |
Total Revenue | $349M |
Cost Of Revenue | $60M |
Costof Goods And Services Sold | $60M |
Operating Income | $59M |
Selling General And Administrative | $225M |
Research And Development | $12M |
Operating Expenses | $230M |
Investment Income Net | - |
Net Interest Income | -$1M |
Interest Income | - |
Interest Expense | $1M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $6M |
Income Before Tax | $57M |
Income Tax Expense | $15M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $42M |
Comprehensive Income Net Of Tax | - |
Ebit | $58M |
Ebitda | $64M |
Net Income | $42M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
MiMedx Group, Inc. (MDXG) is a leading regenerative medicine company headquartered in Marietta, Georgia, specializing in the development and distribution of cutting-edge placental tissue allografts. These innovative products play a vital role in both wound care and surgical applications, significantly enhancing healing processes and improving patient outcomes. Leveraging proprietary technologies and a strong research foundation, MiMedx is strategically positioned to meet the dynamic needs of healthcare providers, while driving advancements in the regenerative medicine sector.